Gilead acquires first TCE asset with $2.2bn Ouro Medicines buyout

Gilead Sciences is acceptable to get Ouro Medicines for $2.2bn, marking the company’s archetypal determination into the T-cell engager (TCE) abstraction and a deepening of ties with semipermanent partner, Galapagos.

Through this deal, the California-based large pharma institution volition manus implicit $1.68bn upfront, portion pledging up to $500m successful milestone payments to sorb the latter’s BCMA/CD3-targeting TCE, gamgertamig (OM336). The therapy is presently successful objective improvement for antibody-mediated orphan diseases specified arsenic immune thrombocytopenia (ITP) and autoimmune haemolytic anaemia (AIHA).

According to Citi analysts, Gilead’s Ouro acquisition some aligns with the large pharma company’s plans to diversify beyond HIV and complements the autoimmune propulsion its subsidiary, Kite is presently making.

While this is each modular protocol for an acquisition, Gilead whitethorn adhd a furniture of complexity to the deal, arsenic the institution is successful late-stage negotiations with Galapagos to co-develop gamgertamig.

Potentially gathering connected the pair’s semipermanent partnership, the acquisition could spot Galapagos articulation the equation by taking connected fractional of the upfront and milestone payments, arsenic good arsenic immoderate costs centred astir registrational trials involving gamgertamig.

In exchange, Galapagos would sorb Ouro’s operating assets and employees, portion securing 20-23% of gamgertamig’s nett income extracurricular of greater China, if the cause were to marque it to market.

Ouro antecedently bought the ex-Greater China rights to gamgertamig from Keymed Biosciences successful January 2025.

Galapagos’ ploy to grow its pipeline comes arsenic the institution goes done a play of important restructuring. In October 2025, the biotech shuttered its compartment therapy unit, marking a determination distant from a modality that has polarised the pharma manufacture successful caller years.

Instead of betting connected compartment therapies, Galapagos plans to thrust its aboriginal occurrence done the acquisition of lucrative pipeline candidates. The biotech volition execute this with its €3bn ($3.5bn) successful currency reserves, which the institution volition usage to get “late-stage” assets successful the immunology and oncology sectors, Galapagos CEO, Henry Gosebruch antecedently told Pharmaceutical Technology.

Currently, Galapagos’ pipeline includes 1 drug, GLPG3667, which the institution is processing for the attraction of systemic lupus erythematosus (SLE) and dermatomyositis. GLPG3667 is an oral tyrosine kinase 2 (TYK2) blocker, which has demonstrated mixed efficacy successful mid-stage trials frankincense far.

In erstwhile years, pharma companies person chiefly developed TCEs for usage successful oncology, with candidates similar Johnson & Johnson’s Tecvayli (teclistamab) and AbbVie & Genmab’s Epkinly (epcoritamab) securing support successful aggregate myeloma and B-cell lymphomas, respectively.